Neurology Clinical Programs
Multiple Sclerosis
Help us fund research
that is changing lives

Let us know about
a "star" employee:

Thanks Program


A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults who are in Early Stages of Treatment for Relapsing Remitting Multiple Sclerosis. The purpose of this study is to evaluate the effectiveness of FDA approved Gilenya 0.5 mg/day versus other FDA approved disease modifying therapies (DMT), through patient retention. The study will include adult patients with relapsing remitting multiple sclerosis,who are in early stages of treatment. For the purpose of this study, early stages of treatment includes patients who either have never been treated with a DMT or who have been treated with no more than one type of DMT for less than or equal to a total of five years of lifetime exposure. Gilenya will be compared to the standard DMTs for multiple sclerosis. Participants will be assigned to receive one of the following treatments:
Gilenya .5 mg/day
DMT (Type of DMT will be determined by the study doctor.)
Participants have a 50% (1 out of 2) chance of being randomly assigned (like flipping a coin) to either Gilenya or a DMT.
The study will take up to 12 months.
If you have been diagnosed with relapsing remitting multiple sclerosis (RRMS), are between the ages of 18-65, are able to come to UCSF for study visits and have not been treated with no more than one class of DMTfor less than or equal to a total of five years of lifetime exposure, you may be eligible to participate.

For more information, contact Jessica Bautista at .(JavaScript must be enabled to view this email address) with "PREFERMS Study Inquiry” in the subject line or at (415) 502-7604.